Comparison of acute versus convalescent stage high-sensitivity C-Reactive protein level in predicting clinical outcome after acute ischemic stroke and impact of erythropoietin

Table 2 Comparisons of Neurological Status and Clinical Outcome between IS Patients with and without EPO Treatment

Variables	Group 1† (n = 80)	Group 2† (n = 80)	P value
NIHSS at 48 h	6.69 ± 4.58	7.30 ± 7.58	0.537
Modified Rankin Scale score at 48 h	3.61 ± 1.42	2.83 ± 1.63	0.109
Barthel Index at 48 h	55.9 ± 31.0	60.6 ± 36.2	0.378
NIHSS on day 90	4.26 ± 5.41	5.53 ± 7.91	0.240
Recurrent stroke, % (n)	0% (0)	8.8% (7)	0.007
90-day mortality, % (n)	2.5% (2)	1.3% (1)	0.560
NIHSS ≥ 8.0	13.8% (11)	28.8% (23)	0.034
Combined MANE, % (n)	16.3% (13)	36.3% (29)	0.007

†: group 1 = with EPO treatment; group 2 = without EPO treatment.
IS = ischemic stroke; MANE = major adverse neurological event (defined as NIHSS ≥ 8, recurrent stroke or death on day 90 after acute IS); NIHSS = national institutes of health stroke scale.

ISSN: 1479-5876